Novo Nordisk (NVO) save Q4, Full Year FY24

Shares Novo Nordisk In the fourth quarter, Wegovy increased by 4.5% after a net profit than expected in their demand for obesity drugs, but demanded a little decline in sale for 2025.

Denmark pharmaceutical pharmacy rose 29%, 28.23 billion dollars Denmark Conic ($ 3.98 billion), 26.09 billion Denmark Kroner is expected.

The full annual net profit defeated the calculations of 100.99 billion billion from 100.99 billion billion billion to 100.99 billion danium croners, 99.14 billion Danish craneans for 2024.

In early deals, the shares increased by 4.5% on Wednesday.

The drug manufacturer placed No. 107% By the end of December, the $ 19.87 billion Denmark craneter ($ 2.76 billion), 20.02 billion dollars ($ 2.76 billion), 20.02 billion dollars) was missing by analysts by analysts by analysts by analysts.

The company’s total sales also produce diabetes and rare disease treatments – 30% and 26% in the fourth quarter, increased by 26% in regular exchange rates. This growth was primarily managed by the demand from North America and Europe, Middle East and Africa.

Novo Nordisk is a slower sales increase in size from 2025 to 24% to 24% from 2025 to 24% from 2025 to 26% for 2024 to 1824 for 2024. Diabetes and obesity care “market.

Novo Nordisk, GLP-1 Agonist threw the wave of global demand rising to the treatment of obesity. GLP-1S, which forms the basis of Novo’s Wegovy and its opponent Eli lilliZepbound, work by imitating a hormone named Peptide-1 like a hormone of the appetite, glucagon.

Investors now follow the company’s updates, including other obesity medicines, including expected experimental Cagrisema. Late-stage Cagrisema test results disappointed In December, 22.7%, 25% of Novo was forecasted after the average weight loss in the markets.

Test results, Cagrisema’s Novo’s next generation of Nova will appear as the next generation of obesity medication, the active ingredient – amillin analog coagrrrrrrrrrrrrrrrrrrrrrrrorrintide The form of weight loss treatment.

But the positive Early stage results Once the Amylin was similar to the amylin’s pancreas hormone, for Amycret’s medication, last month’s shares increased last month.

Novo Nordisk, on Wednesday, in 2025, CAGRISEMA will hold another research in the first quarter of 2026 to approve the regulation in the first quarter of 2026.

This is a broken news story and will be updated shortly.